However, while shPSMD3 increased apoptosis of CML cell lines in the presence and absence of therapy [21], the phenotype was different in FLT3-mutated AML cell lines. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.